Literature DB >> 34305287

Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis.

Mohamed Eissa1, Selmy Awad2, Somaya Barakat3, Ahmed Saleh1, Salah Rozaik1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Early detection of HCC is always a challenging task for physicians. Serum Golgi protein 73 (GP73) is considered a potential tumor marker for the detection of HCC. However, the diagnostic value of GP73 for the HCC diagnosis is still controversial. This research was designed to assess the diagnostic efficacy of GP73 as a diagnostic tool for HCC in cases with hepatitis C virus-related cirrhosis.
METHODS: Eighty-seven subjects were allocated into four different groups in this prospective research (HCC, liver cirrhosis, chronic hepatitis C, and healthy control group). Serum alpha-fetoprotein (AFP) and GP73 were tested for all subjects in the study. Detection of focal hepatic lesions was based on imaging by abdominal ultrasonography and triphasic computed tomography.
RESULTS: The cut-off values for GP73 and AFP were 534.5 ng/L and 32 ng/mL, respectively. The specificity of GP73 was 87%, and the sensitivity was 88%, while the specificity and sensitivity of AFP levels were 80% and 72%, respectively. The negative predictive value of GP73 was 87.5%, and the positive predictive value of GP73 was 84.6%, while the same parameters of AFP were 73.1% and 75%, respectively.
CONCLUSION: Serum Golgi protein 73 could be a valuable biomarker and a useful diagnostic tool for the early diagnosis of HCC in cases of hepatitis C virus-related cirrhosis.
© 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Alpha-fetoprotein; Golgi protein 73; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis

Year:  2021        PMID: 34305287      PMCID: PMC8282533          DOI: 10.1016/j.mjafi.2020.11.013

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  19 in total

Review 1.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

2.  Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma.

Authors:  Abeer M Nafee; Heba F Pasha; Salah M Abd El Aal; Naglaa A Mostafa
Journal:  Clin Biochem       Date:  2012-05-02       Impact factor: 3.281

Review 3.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

4.  Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis.

Authors:  Jing Yang; Jingjing Li; Weiqi Dai; Fan Wang; Miao Shen; Kan Chen; Ping Cheng; Yan Zhang; Chengfen Wang; Rong Zhu; Huawei Zhang; Yuanyuan Zheng; Junshan Wang; Yujing Xia; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  Exp Ther Med       Date:  2015-01-29       Impact factor: 2.447

Review 5.  Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.

Authors:  T Kimhofer; H Fye; S Taylor-Robinson; M Thursz; E Holmes
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

Review 6.  Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Authors:  Massimiliano Berretta; Carla Cavaliere; Lara Alessandrini; Brigida Stanzione; Gaetano Facchini; Luca Balestreri; Tiziana Perin; Vincenzo Canzonieri
Journal:  Oncotarget       Date:  2017-02-21

7.  Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.

Authors:  Tianhui Liu; Mingjie Yao; Shuhong Liu; Lu Wang; Leijie Wang; Jinlin Hou; Xiong Ma; Jidong Jia; Jingmin Zhao; Hui Zhuang; Fengmin Lu
Journal:  Oncotarget       Date:  2017-03-07

8.  Studying the Impact of Golgi Protein 73 Serving as a Candidate Biomarker in Early Diagnosis for Hepatocellular Carcinomazzm321990among Saudi Patients

Authors:  Randa Mohamed Ahmed Farag; Dujana Al Ayobi; Khalid A Alsaleh; Hye-Joo Kwon; Afaf EL-Ansary; Emad Anwar Dawoud
Journal:  Asian Pac J Cancer Prev       Date:  2019-01-25

9.  Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma.

Authors:  Zhiguo Zhang; Yanying Zhang; Yeying Wang; Lingling Xu; Wanju Xu
Journal:  Onco Targets Ther       Date:  2015-12-31       Impact factor: 4.147

10.  The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis.

Authors:  Shoujie Zhao; Min Long; Xiangnan Zhang; Shixiong Lei; Weijia Dou; Jie Hu; Xilin Du; Lei Liu
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.